Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Puma Biotechnology Sees Q3 Revenue $50M-$53M Vs $57.85M Est.; FY24 Revenue $183M-$190M Vs $217.63M Est.

Author: Benzinga Newsdesk | August 01, 2024 05:38pm

Third Quarter and Full Year 2024 Financial Outlook

 Third Quarter 2024Full Year 2024
Net Product Revenue$50 -53 million$183 - $190 million
Royalty Revenue$20 - $22 million$30 - $33 million
License Revenue$0 million$1 - $2 million
Net Income$11 - $13 million$12 - $15 million
Gross to Net Adjustment18.5% - 19.5%21% - 22%


 

Posted In: PBYI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist